Department of Clinical, Neuro and Developmental Psychology, Faculty of Behavioural and Movement Sciences, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, van der Boechorststraat 7, 1081 BT, Amsterdam, The Netherlands.
Cancer Center Amsterdam (CCA), Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.
Trials. 2020 Jan 31;21(1):124. doi: 10.1186/s13063-019-4037-5.
Incurable cancer does not only affect patients, it also affects the lives of their partners. Many partners take on caregiving responsibilities. The burden of these caregiving tasks are often associated with physical, psychological, and social difficulties and many partners have unmet supportive care needs. Oncokompas is an eHealth self-management application to support partners in finding and obtaining optimal supportive care, tailored to their quality of life and personal preferences. A randomized controlled trial will be carried out to determine the efficacy and cost-utility of Oncokompas.
A total of 136 adult partners of patients with incurable cancer will be included. Partners will be randomly assigned to the intervention group, which directly gets access to Oncokompas, or the waiting-list control group, which gets access to Oncokompas after three months. The primary outcome measure is caregiver burden. Secondary outcome measures comprise self-efficacy, health-related quality of life, and costs. Measures will be assessed at baseline, two weeks after randomization, and three months after the baseline measurement.
This study will result in evidence on the efficacy and cost-utility of Oncokompas among partners of patients with incurable cancer, which might lead to implementation of Oncokompas as a health service for partners of patients with incurable cancer.
Netherlands Trial Register, NTR 7636. Registered on 23 November 2018.
绝症不仅影响患者,还影响其伴侣的生活。许多伴侣承担起照顾者的责任。这些照顾任务的负担常常与身体、心理和社会困难有关,许多伴侣的支持性护理需求未得到满足。Oncokompas 是一种电子健康自我管理应用程序,旨在支持伴侣寻找和获得最佳的支持性护理,根据他们的生活质量和个人偏好进行定制。将开展一项随机对照试验,以确定 Oncokompas 的疗效和成本效用。
总共将纳入 136 名绝症患者的成年伴侣。伴侣将被随机分配到干预组,直接获得 Oncokompas,或等待名单对照组,在三个月后获得 Oncokompas。主要结局指标是照顾者负担。次要结局指标包括自我效能感、健康相关生活质量和成本。在基线、随机分组后两周和基线测量后三个月进行测量。
这项研究将为绝症患者的伴侣使用 Oncokompas 的疗效和成本效用提供证据,这可能导致将 Oncokompas 作为绝症患者伴侣的一项健康服务实施。
荷兰试验注册中心,NTR 7636。于 2018 年 11 月 23 日注册。